Article in PDF
How to Cite
Citation Manager
Readers' Comments (0)
Audio Visual Article Statistics
Link
to PUBMED
Print this Article
Send to a Friend
Advertisers
Access Statistics Resources
Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."
Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011
Dr. Shankar P.R.
"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."
Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011 Anuradha
Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.
Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020
Original article / research
Full Version
Efficacy of Ceftazidime-avibactam against Multidrug-resistant Gram-negative Pathogens in ICU Patients: A Cross-sectional Study from a Subhimalayan Tertiary Care Hospital
Correspondence Address :
Rajender Singh,
Associate Professor, Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttrakhand, India.
E-mail: panwar.rajendra@gmail.com
Introduction: Antimicrobial Resistance (AMR) is a pressing global health issue, posing challenges in clinical management, increasing morbidity and mortality rates, and burdening healthcare systems economically. The present study assesses the in-vitro efficacy of Ceftazidime-Avibactam (CZA) against Multidrug-Resistant (MDR) Gram-negative isolates from Intensive Care Unit (ICU) patients, comparing it to other beta-lactam/beta-lactamase inhibitors, with a focus on Carbapenem-Resistant Enterobacterales (CRE), Extended-Spectrum Beta-Lactamase (ESBL)- producing Enterobacterales, and MDR Pseudomonas aeruginosa.
Aim: To determine the sensitivity pattern of CZA against various MDR Gram-negative isolates from ICU patient samples and compare its efficacy with other second-line drugs.
Materials and Methods: The present cross-sectional observational study was conducted over a six-month period from January to June 2021 on 94 MDR bacterial isolates obtained from Intensive Care ICU patients at the Himalayan Institute of Medical Sciences (HIMS), Swami Rama Himalayan University (SRHU) Dehradun, Uttrakhand, India. All clinical samples received from ICU patients with clinically suspected sepsis were included in the study. These samples were routinely processed in the bacteriology laboratory following Standard Operating Procedures (SOPs). Bacterial identification and Antimicrobial Susceptibility Testing (AST) were performed using the VITEK-2 automated system from bacterial colonies isolated after overnight incubation. Demographic characteristics of the patients were systematically recorded and analysed. E-test strips for CZA were only applied to those bacterial isolates identified as MDR Enterobacteriaceae and Pseudomonas spp. Statistical analyses were conducted to determine antimicrobial susceptibility rates, with statistical significance set at p<0.05.
Results: Among the 94 MDR Gram-negative isolates, Klebsiella pneumoniae and Escherichia coli were the most prevalent pathogens, comprising 34 (36.2%) and 32 (34.0%) of samples, respectively. CZA demonstrated a sensitivity rate of 35 (37.2%) across 94 samples, with limited efficacy against 46 CRE isolates i.e., 10(21.7%) and 15 MDR Pseudomonas aeruginosa i.e., 4 (26.6%), and no efficacy against Acinetobacter baumannii 0 (0%). Notably, CZA outperformed amoxicillin-clavulanic acid and piperacillin-tazobactam in-vitro activity against ESBL-producing Enterobacteriaceae but showed reduced efficacy against 61 carbapenem resistant isolates when compared to last-resort antibiotics like colistin 39 (63.9%).
Conclusion: The findings indicate CZA’s moderate efficacy against ESBL-producing Gram-negative bacteria but limited effectiveness against CRE and MDR P. aeruginosa in ICU settings. These results suggest a need for careful evaluation of CZA use in ICU settings and highlight the importance of ongoing antimicrobial surveillance and the potential for combination therapy to address rising MDR infections.
Antimicrobial resistance, Bacterial identification, Beta-lactamase, Intensive care unit
DOI: 10.7860/JCDR/2025/76821.22033
Date of Submission: Nov 13, 2024
Date of Peer Review: Mar 18, 2025
Date of Acceptance: May 24, 2025
Date of Publishing: Nov 01, 2025
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Nov 14, 2024
• Manual Googling: May 20, 2025
• iThenticate Software: May 22, 2025 (7%)
ETYMOLOGY: Author Origin
EMENDATIONS: 7
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase
- EBSCOhost
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)
- www.omnimedicalsearch.com